AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Lifecare ASA

Share Issue/Capital Change Sep 30, 2024

3654_rns_2024-09-30_69ac2f01-bcdb-4db3-93e2-6446ad44d388.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

Lifecare ASA: Share consolidation (reverse split) and change of par value

Lifecare ASA: Share consolidation (reverse split) and change of par value

Reference is made to the extraordinary general meeting in Lifecare ASA (the

"Company") held on 17 September 2024, where it was resolved to carry out a

share consolidation (reverse split) in the ratio of 13:1.

The share consolidation has now been registered with the Norwegian Register of

Business Enterprises, and the Company's share capital is NOK 78,112,907.60

(unchanged) divided on 15,021,713 shares, each with a nominal value of NOK

5.20.

About Lifecare:

Lifecare is a clinical stage medical sensor company developing technology for

sensing and monitoring of various body analytes. Lifecare's main focus is to

bring the next generation of Continuous Glucose Monitoring ("CGM") systems to

market. Lifecare enables osmotic pressure as sensing principle, combined with

the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR")

on the sensor body for read-out of pressure variations. Lifecare's sensor

technology is referred to as "Sencell" and is suitable for identifying and

monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, [email protected], +47 40 05 90 40

Renete Kaarvik, CFO, [email protected], +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities

Trading Act, §5-12. The information was submitted for publication at

2024-09-30 17:31 CEST.

Talk to a Data Expert

Have a question? We'll get back to you promptly.